Literature DB >> 9293770

Evaluation of the role of the 3'alpha heavy chain enhancer [3'alpha E(hs1,2)] in Vh gene somatic hypermutation.

K M Tumas-Brundage1, K A Vora, T Manser.   

Abstract

Previous work on the cis-acting elements that control heavy chain variable region (VH) gene somatic hypermutation has indicated the presence of an as yet unidentified element(s) 3' of the intron enhancer that is necessary for high rate mutation. Examination of cis-acting elements involved in kappa light chain V gene hypermutation has demonstrated a requirement for both the intronic and 3' kappa enhancers in this process. To examine whether the 3'alpha heavy chain enhancer [3'alpha E(hs1,2)] is required for somatic hypermutation of VH genes, we generated two types of transgenic mice. One type was generated using a construct containing a VH promoter, a rearranged VDJ, the heavy chain intronic enhancer, and the murine heavy chain 3'alpha E(hs1,2). The transgenes in the second lines were similar to the transgenes in the first with the addition of a second complete matrix attachment region (MAR) 3' of the heavy chain intronic enhancer, and splice acceptor and polyadenylation sites between the two enhancers. Analysis of both transgenes revealed levels of mutation at least 10-fold lower than endogenous VH genes. These data suggest that the 3'alpha E(hs1,2) does not play a role analogous to the 3' kappa enhancer in the regulation of the hypermutation process. Moreover, in one of the transgenes, the presence of the 3'alpha E(hs1,2) resulted in a lack of transcription in vivo, suggesting a negative regulatory role for this enhancer in certain contexts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293770     DOI: 10.1016/s0161-5890(97)00065-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

Review 1.  Somatic hypermutation in human B cell subsets.

Authors:  N S Longo; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  The HoxC4 homeodomain protein mediates activation of the immunoglobulin heavy chain 3' hs1,2 enhancer in human B cells. Relevance to class switch DNA recombination.

Authors:  Edmund C Kim; Christopher R Edmonston; Xiaoping Wu; András Schaffer; Paolo Casali
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

3.  Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEmu enhancer and 3'Ealpha enhancers in human lymphoblastoid B cells.

Authors:  Atsumasa Komori; Zhenming Xu; Xiaoping Wu; Hong Zan; Paolo Casali
Journal:  Mol Immunol       Date:  2006-01-10       Impact factor: 4.407

4.  Complex regulation of somatic hypermutation by cis-acting sequences in the endogenous IgH gene in hybridoma cells.

Authors:  Diana Ronai; Maria Dolores Iglesias-Ussel; Manxia Fan; Marc J Shulman; Matthew D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

5.  Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting.

Authors:  Ravi K Dinesh; Benjamin Barnhill; Anoj Ilanges; Lizhen Wu; Daniel A Michelson; Filip Senigl; Jukka Alinikula; Jeffrey Shabanowitz; Donald F Hunt; David G Schatz
Journal:  Eur J Immunol       Date:  2019-12-19       Impact factor: 5.532

6.  AID-targeting and hypermutation of non-immunoglobulin genes does not correlate with proximity to immunoglobulin genes in germinal center B cells.

Authors:  Hillary Selle Gramlich; Tara Reisbig; David G Schatz
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers.

Authors:  J P Manis; N van der Stoep; M Tian; R Ferrini; L Davidson; A Bottaro; F W Alt
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

8.  The IgH 3' regulatory region controls somatic hypermutation in germinal center B cells.

Authors:  Pauline Rouaud; Christelle Vincent-Fabert; Alexis Saintamand; Rémi Fiancette; Marie Marquet; Isabelle Robert; Bernardo Reina-San-Martin; Eric Pinaud; Michel Cogné; Yves Denizot
Journal:  J Exp Med       Date:  2013-07-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.